

Heart medication and metabolism: What physicians should reflect on to keep them in harmony

Cardiovascular diseases are the leading cause of death globally and have been for a long time. This spotlight has ensured that doctors treating patients with heart problems have a wide variety of medications to work with. Most of the time, these medications are used to address direct and immediate problems the heart is dealing with. The catch is that apart from this direct and intended effect, heart medications have additional and easier to overlook effects on the metabolism. A recent review article (1) has described how commonly prescribed heart medications could be making both beneficial and harmful changes in the metabolism of the heart and the rest of the body. These changes are important for physicians to be aware of to make sure that they are doing the most good and the least harm when deciding what medications to prescribe.

Metabolic derangements have long been recognized as playing an important role in the pathophysiology of cardiovascular diseases. Metabolic impairment is not just a feature of the heart, but rather a global issue with important contributions from organs and peripheral tissues. Prescription of cardiac medications is aimed towards the pathophysiological mechanisms underlying the disease process. For instance, inhibition of the renin-angiotensin-aldosterone and sympathetic nervous systems is directed towards ameliorating abnormal neuro-hormonal activation. However, apart from their primary therapeutic actions, these drugs may positively also affect the global and cardiac metabolism. Similarly, a positive ancillary metabolic effect has also been observed with ARNI (angiotensin receptor neprilysin inhibitor), acetylsalicylic acid, trimetazidine, ranolazine, ivabradine, alpha blockers, central sympathetic inhibitors. On the contrary, among the others, thiazide diuretics, mineral corticoid receptor antagonists, calcium channel blockers, unfractionated heparin, direct thrombin inhibitors, specific statins, have all been shown to impair different metabolic functions. In this context it is interesting to note the recent demonstration of the beneficial effect of sodium-glucose transport protein 2 inhibitors (SGLT2i) in diabetic and non-diabetic in cardiac patients, indicating that the cardiovascular effects of these drugs are largely independent from glucose lowering. These findings will necessarily lead to the need to re-consider this class of drugs not as solely a glucose lowering drug but as metabolic cardiovascular drugs.

Overall, it is clear that additional pharmacological actions may be of special interest for both potential beneficial and deleterious effects and should be well understood and known by all providers managing patients with cardiovascular diseases. In table 1 are a few examples of effects from commonly prescribed medications in cardiac patients.

1/3



Atlas of Science

another view on science https://atlasofscience.org

Peta adriency is receptor blockers Reduction of peripheral lipolysis Reduction of circulating levels of free fatty acids Increased carbohydrates utilization Improved insulin sensitivity (carvedilol) Angiotenisin-converting enzyme inhibitors and angiotenian receptor blockers Mineralocorticod receptor antagonists Mineralocorticod receptor experimental effects on glucose and lipid homeostasis by increased corticol levels through blockade of the glucocorticoid receptors However, epierenone appears devoid of metabolic effects Angiotensian receptor-neprilysian Feduced insulin sensitivity Greater reduction in Habita Compared to ACE-inhibitor enalapril receptors However, epierenone appears devoid of metabolic effects Angiotensian receptor-neprilysian Reduced insulin resistance (chiazide diuretics) Induced insulin resistance (thiazide diuretics) Induced insulin resistance (thiazide diuretics) Induced electrolyte depletion (thiazide and loop diuretics) Activation of neuro-hormonal systems (loop diuretics) Activation of neuro-hormonal systems (loop diuretics) Activation of neuro-hormonal systems (loop diuretics) Increased glucosuria triggers lipolysis and fatty acid oxidation and ketone body synthesis in the liver Increased glucosuria triggers lipolysis and fatty acid oxidation and ketone body synthesis in the liver Increased glucosuria triggers lipolysis and fatty acid oxidation and ketone body synthesis in the liver Increased glucosuria triggers lipolysis and fatty acid oxidation in provide in the lipolysis and fatty acid oxidation in provide in provide weight loss Acetylsalicytic acid Acetylsalicytic acid	Medications	Metabolic effects
Reduction of circulating levels of free fatty acids	Beta adrenergic receptor	Reduction of peripheral lipolysis
Increased carbohydrates utilization Improved insulin sensitivity (carvedilot) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers Reduction in the incidence of diabetes Needuction in the incidence of diabetes Provided insulin sensitivity Increased cortisol levels through blockade of the glucocorticoid receptor antagonists Improved insulin sensitivity Increased ATP production and calcium retention capacity Induced dyslipidemia (thizated diuretics) Induced dyslipidemia (thizated diuretics) Induced dyslipidemia (thizated diuretics) Induced descriptive depletion (thizated and loop diuretics) Induced electrolyte depletion (thizated and loop diuretics) Induced electrolyte depletion (thizated and loop diuretics) Increased diuresis resulting in reduction in plasma volume and blood pressure Gliucagon-like peptide 1 Improve incidin resistance		
- Improved insulin sensitivity (carvedioi) - Anglotensin-converting energyme inhibitors and angiotensin receptor blockers - Reduction in the incidence of diabetes - Reduction in the incidence of diabetes - Detrimental effects on glucose and lipid homeostasis by increased cortisol levels through blockade of the glucocorticold receptor exceptors - However, epierenone appears devoid of metabolic effects - However, epierenone appears devoid evierention of the effects - However, epierenone appears devoid evierention of effects - However, epierenone appears devoid of metabolic effects - However, epierenone evierention in Hoha of evierention of effects - However, epierenone evierention in Hoha of evierention effects - However, epierenone evierention effects - However, epierenone evierention effects - However, epierenone evierention in Hoha of evierention effects - However, epierenone evierention effects - However, epierenone evierention effects - However, epierenone evierention effects - Howeve		
Angiotensin-converting encyme inhibitors and angiotenian receptor blockers Reduction in the incidence of diabetes Reduction of neuro-formonal systems (loop diabetes) Reduction of neuro-hormonal systems (loop diaretics) Reduction of neuro-hormonal systems (loop diaretics) Reduction of neuro-hormonal systems (loop diaretics) Reduction of insulin and inhibition of glucagon secretion Improve insulin resistance Peromote weight loss Reduction of insulin and inhibition of glucagon secretion Improve insulin resistance Peromote weight loss Reduction of catabolic pathways (glucose uptake and FFA oxidation) Inhibition of the transcription factor NF-kappa B (improved glucose tolerance) Reduction in fatty acid oxidation Improve disponsible servant setosterone levels Reduction of infatty acid oxidation Improve disponsible servant setosterone levels Reduction of infatty acid oxidation Improve disponsible servant setosterone levels Reduction of infatty acid oxidation Improve disponsible servant setosterone levels Reduction of fire acid sodium current, thereby reducing the accumulation of infatty acid oxidation Increased glucose oxidation		
analytenian receptor biockers Nineralocorticoid receptor analogictenian receptor biockers Nineralocorticoid receptor analogonists Nineralocorticoid receptor historian in the incidence of diabetes Nineralocorticoid receptor historian in the incidence of diabetes Nineralocorticoid receptors Noneralocorticoid receptor historian in the incidence of diabetes Anglotensian receptor-neprilysian inhibitors Anglotensian receptor-neprilysian inhibitors Irichannel Inhibitor Irichannel Inhibitor Irichannel Inhibitor Irichannel Inhibitor Increased ATP production and calcium retention capacity Induced dyslipidemia (thiazide diuretics) Induced dyslipidemia (thiazide diuretics) Induced describita describitates (thiazide diuretics) Induced electrolyte depletion (thiazide and loop diuretics) Induced lossilian resistance Increased diuresis resulting in reduction in plasma volume and blood pressure Glucagon-like peptide 1 aponists Improve peptide 1 aponists Improve peptide 1 aponists Increased diuresis resulting in reduction in plasma volume and blood pressure Increased diuresis resulting in reduction in plasma volume and blood pressure Increased plucose original plucose plucose original plucose original plucose original plucose original plucose original plucose original plucose in pluc	Angiotensin-converting	
Post	enzyme inhibitors and	
increased cortisol levels through blockade of the glucocorticoid receptors However, eplerenone appears devoid of metabolic effects Angiotensin receptor-neprilysin Imbibitors Greater reduction in HbA1c compared to ACE-inhibitor enalapril Inchannel inhibitor (Ivabradine) Reduced mitochondrial reactive oxygen species formation (Ivabradine) Induced dyslipidemia (thiazide diuretics) Induced insulin resistance (thiazide diuretics) Induced electrolyte depletion (thiazide and loop diuretics) Activation of neuro-hormonal systems (loop diuretics) Induced electrolyte depletion (thiazide and loop diuretics) Activation of neuro-hormonal systems (loop diuretics) Induced electrolyte depletion (thiazide and loop diuretics) Activation of neuro-hormonal systems (loop diuretics) Activation of neuro-hormonal systems (loop diuretics) Activation of insulin and inhibition of glucagon secretion improved electrolyte insulin resistance Promote weight loss Acetylsalicytic acid Reduction of circulating FFA, by activating AMP-activated protein kinase Activation of catabolic pathways (glucose uptake and FFA oxidation) Inhibition of the transcription factor NF-kappa B (improved glucose tolerance) Statins Pravastatin decreases the risk of development of diabetes All statins reduce serum testosterone levels Trimetazidine Reduced in fatty acid oxidation Improve glycolysis and glucose oxidation Improve glycolysis and glucose oxidation Increased glucose oxidation Increased glucose oxidation Uctamin D Induced weight gain and insulin resistance		
However, eplerenone appears devoid of metabolic effects Improved insulin sensitivity Greater reduction in HbA1c compared to ACE-inhibitor enalapril Inchannel inhibitor (Ivabradine) Reduced mitochondrial reactive oxygen species formation Increased ATP production and calcium retention capacity Induced dyslipidemia (thiazide diuretics) Induced insulin resistance (thiazide diuretics) Elevated parathyroid hormone level (loop diuretics) Induced electrolyte depletion (thiazide and loop diuretics) Induced electrolyte depletion (thiazide and loop diuretics) Induced electrolyte depletion (thiazide and loop diuretics) Activation of neuro-hormonal systems (loop diuretics) Induced electrolyte depletion (thiazide and loop diuretics) Induced electrolyte depletion (thiazide diuretics) Increased diuresis resulting in reduction in plasma volume and belood pressure Increased electrolyte depletion of insulin and inhibition of glucagon secretion Improve dividention of circulating FFA, by activating AMP-activated protein kinase Activation of catabolic pathways (glucose uptake and FFA oxidation) Inhibition of the transcription factor NF-kappa B (improved glucose tolerance) Statins Pravastatin decreases the risk of development of diabetes Other statins including simvastatin, atorvastatin, and resultation of instrument in insulin resistance Trimetazidine Reduction in fatty acid oxidation Increased glucose oxidation I		
However, eplerenone appears devoid of metabolic effects Improved insulin sensitivity Greater reduction in HbA1c compared to ACE-inhibitor enalapril Inchannel inhibitor (Ivabradine) Reduced mitochondrial reactive oxygen species formation Increased ATP production and calcium retention capacity Induced dyslipidemia (thiazide diuretics) Induced insulin resistance (thiazide diuretics) Elevated parathyroid hormone level (loop diuretics) Induced electrolyte depletion (thiazide and loop diuretics) Induced electrolyte depletion (thiazide and loop diuretics) Induced electrolyte depletion (thiazide and loop diuretics) Activation of neuro-hormonal systems (loop diuretics) Induced electrolyte depletion (thiazide and loop diuretics) Induced electrolyte depletion (thiazide diuretics) Increased diuresis resulting in reduction in plasma volume and belood pressure Increased electrolyte depletion of insulin and inhibition of glucagon secretion Improve dividention of circulating FFA, by activating AMP-activated protein kinase Activation of catabolic pathways (glucose uptake and FFA oxidation) Inhibition of the transcription factor NF-kappa B (improved glucose tolerance) Statins Pravastatin decreases the risk of development of diabetes Other statins including simvastatin, atorvastatin, and resultation of instrument in insulin resistance Trimetazidine Reduction in fatty acid oxidation Increased glucose oxidation I		receptors
Inhibitors Greater reduction in HibAtc compared to ACE-inhibitor enalapril Inchannel inhibitor ((Vabradine) Reduced mitochondrial reactive oxygen species formation Increased ATP production and calcium retention capacity Induced dyslipidemia (thiazide diuretics) Induced disulin resistance (thiazide diuretics) Elevated parathyroid hormone level (loop diuretics) Induced electrolyte depletion (thiazide and loop diuretics) Activation of neuro-hormonal systems (loop diuretics) Activation of neuro-hormonal systems (loop diuretics) Increased glucosuria triggers lipolysis and fatty acid oxidation and ketone body synthesis in the liver Increased diuresis resulting in reduction in plasma volume and blood pressure Glucagon-like peptide 1 agonists Acetylsalicylic acid Reduction of insulin and inhibition of glucagon secretion Improve insulin resistance Promote weight loss Acetylsalicylic acid Reduction of circulating FFA, by activating AMP-activated protein kinase Activation of catabolic pathways (glucose uptake and FFA oxidation) Inhibition of the transcription factor NF-kappa B (improved glucose tolerance) Trimetazidine Pravastatin decreases the risk of development of diabetes Other statins including simvastatin, and rosuvastatin, and rosuvastatin increase the risk of development of diabetes All statins reduce serum testosterone levels Trimetazidine Reduction in fatty acid oxidation Improved glycolysis and glucose oxidation Antioxidant activity Reduced endothelin-1 release Modulation of Intracellular Ca ⁺⁺ Increased glucose oxidation Lowered plasma glucose and HbA1C levels CPT-1 inhibitors Reduction of FFA oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Improvement in insulin resistance		
Inhibitors Greater reduction in HibAtc compared to ACE-inhibitor enalapril Inchannel inhibitor ((Vabradine) Reduced mitochondrial reactive oxygen species formation Increased ATP production and calcium retention capacity Induced dyslipidemia (thiazide diuretics) Induced disulin resistance (thiazide diuretics) Elevated parathyroid hormone level (loop diuretics) Induced electrolyte depletion (thiazide and loop diuretics) Activation of neuro-hormonal systems (loop diuretics) Activation of neuro-hormonal systems (loop diuretics) Increased glucosuria triggers lipolysis and fatty acid oxidation and ketone body synthesis in the liver Increased diuresis resulting in reduction in plasma volume and blood pressure Glucagon-like peptide 1 agonists Acetylsalicylic acid Reduction of insulin and inhibition of glucagon secretion Improve insulin resistance Promote weight loss Acetylsalicylic acid Reduction of circulating FFA, by activating AMP-activated protein kinase Activation of catabolic pathways (glucose uptake and FFA oxidation) Inhibition of the transcription factor NF-kappa B (improved glucose tolerance) Trimetazidine Pravastatin decreases the risk of development of diabetes Other statins including simvastatin, and rosuvastatin, and rosuvastatin increase the risk of development of diabetes All statins reduce serum testosterone levels Trimetazidine Reduction in fatty acid oxidation Improved glycolysis and glucose oxidation Antioxidant activity Reduced endothelin-1 release Modulation of Intracellular Ca ⁺⁺ Increased glucose oxidation Lowered plasma glucose and HbA1C levels CPT-1 inhibitors Reduction of FFA oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Improvement in insulin resistance	Angiotensin receptor-neprilysin	Improved insulin sensitivity
(Ivabradine) Increased ATP production and calcium retention capacity Induced dyslipidemia (thiazide diuretics) Induced insulin resistance (thiazide diuretics) Elevated parathyroid hormone level (loop diuretics) Induced electrolyte depletion (thiazide and loop diuretics) Activation of neuro-hormonal systems (loop diuretics) Increased glucosuria triggers lipolysis and fatty acid oxidation and ketone body synthesis in the liver Increased diuresis resulting in reduction in plasma volume and blood pressure Glucagon-like peptide 1 agonists Augmentation of insulin and inhibition of glucagon secretion Improve insulin resistance Promote weight loss Acetylsalicylic acid Reduction of circulating FFA, by activating AMP-activated protein kinase Activation of catabolic pathways (glucose uptake and FFA oxidation) Inhibition of the transcription factor NF-kappa B (improved glucose tolerance) Statins Pravastatin decreases the risk of development of diabetes Other statins including simvastatin, atorvastatin, and rosuvastatin increase the risk of development of diabetes All statins reduce serum testosterone levels Trimetazidine Reduction in fatty acid oxidation Improved glycolysis and glucose oxidation Antioxidant activity Reduced endothelin-1 release Ranolazine Modulation of late sodium current, thereby reducing the accumulation of intracellular Ca++ Increased glucose oxidation Lowered plasma glucose and HbA1C levels CPT-I inhibitors Reduction of FFA oxidation Improvement in insulin resistance Psychotropic drugs Induced weight gain and insulin resistance		
Diuretics Induced dyslipidemia (thiazide diuretics) Induced dyslipidemia (thiazide diuretics) Induced dyslipidemia (thiazide diuretics) Elevated parathyroid hormone level (loop diuretics) Activation of neuro-hormonal systems (loop diuretics) Increased glucosuria triggers lipolysis and fatty acid oxidation and ketone body synthesis in the liver Increased diuresis resulting in reduction in plasma volume and blood pressure Augmentation of insulin and inhibition of glucagon secretion in plasma volume and blood pressure Improve insulin resistance Promote weight loss Acetylsalicylic acid Reduction of circulating FFA, by activating AMP-activated protein kinase Activation of catabolic pathways (glucose uptake and FFA oxidation) Inhibition of the transcription factor NF-kappa B (improved glucose tolerance) Statins Pravastatin decreases the risk of development of diabetes Other statins including simvastatin, atorvastatin, and rosuvastatin increase the risk of development of diabetes All statins reduce serum testosterone levels Trimetazidine Reduction in fatty acid oxidation Improved glycolysis and glucose oxidation Antioxidant activity Reduced endothelin-1 release Modulation of late sodium current, thereby reducing the accumulation of intracellular Ca++ Increased glucose oxidation Lowered plasma glucose and HbA1C levels CPT-1 Inhibitors Reduction of FFA oxidation Increased glucose oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Vitamin D Stimulation of insulin secretion Improvement in insulin resistance		Reduced mitochondrial reactive oxygen species formation
Induced insulin resistance (thiazide diuretics) Elevated parathyroid hormone level (loop diuretics) Induced electrolyte depletion (thiazide and loop diuretics) Activation of neuro-hormonal systems (loop diuretics) Activation of neuro-hormonal systems (loop diuretics) Increased glucosuria triggers lipolysis and fatty acid oxidation and ketone body synthesis in the liver Increased diuresis resulting in reduction in plasma volume and blood pressure Improve insulin resistance Promote weight loss Reduction of circulating FFA, by activating AMP-activated protein kinase Activation of catabolic pathways (glucose uptake and FFA oxidation) Inhibition of the transcription factor NF-kappa B (improved glucose tolerance) Statins Pravastatin decreases the risk of development of diabetes Other statins including simvastatin, atorvastatin, and rosuvastatin increase the risk of development of diabetes All statins reduce serum testosterone levels All statins reduce serum testosterone levels Trimetazidine Reduction in fatty acid oxidation Improved glycolysis and glucose oxidation Antioxidant activity Reduced endothelin-1 release Modulation of late sodium current, thereby reducing the accumulation of intracellular Ca** Increased glucose oxidation Lowered plasma glucose and HbA1C levels Prefit inhibitors Reduction of FFA oxidation Increased glucose oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Up-regulation of insulin secretion Improvement in insulin resistance Psychotropic drugs Induced weight gain and insulin resistance	(Ivabradine)	Increased ATP production and calcium retention capacity
Elevated parathyroid hormone level (loop diuretics) Induced electrolyte depletion (thiazide and loop diuretics) Activation of neuro-hormonal systems (loop diuretics) Activation of neuro-hormonal systems (loop diuretics) Increased glucosuria triggers lipolysis and fatty acid oxidation and ketone body synthesis in the liver Increased diuresis resulting in reduction in plasma volume and blood pressure Augmentation of insulin and inhibition of glucagon secretion Improve insulin resistance Promote weight loss Acetylsalicylic acid Reduction of circulating FFA, by activating AMP-activated protein kinase Activation of catabolic pathways (glucose uptake and FFA oxidation) Inhibition of the transcription factor NF-kappa B (improved glucose tolerance) Statins Pravastatin decreases the risk of development of diabetes Other statins including simvastatin, atorvastatin, and rosuvastatin increase the risk of development of diabetes All statins reduce serum testosterone levels Trimetazidine Reduction in fatty acid oxidation Improved glycolysis and glucose oxidation Antioxidant activity Reduced endothelin-1 release Ranolazine Modulation of late sodium current, thereby reducing the accumulation of intracellular Ca** Increased glucose oxidation Lowered plasma glucose and HbA1C levels CPT-I inhibitors Reduction of FFA oxidation Increased glucose oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Vitamin D Stimulation of insulin secretion Improvement in insulin resistance	Diuretics	Induced dyslipidemia (thiazide diuretics)
Induced electrolyte depletion (thiazide and loop diuretics) Activation of neuro-hormonal systems (loop diuretics) Increased glucosuria triggers lipolysis and fatty acid oxidation and ketone body synthesis in the liver Increased diuresis resulting in reduction in plasma volume and blood pressure Augmentation of insulin and inhibition of glucagon secretion Improve insulin resistance Promote weight loss Acetylsalicylic acid Reduction of circulating FFA, by activating AMP-activated protein kinase Activation of catabolic pathways (glucose uptake and FFA oxidation) Inhibition of the transcription factor NF-kappa B (improved glucose tolerance) Statins Pravastatin decreases the risk of development of diabetes Other statins including simvastatin, atorvastatin, and rosuvastatin increase the risk of development of diabetes All statins reduce serum testosterone levels Trimetazidine Reduction in fatty acid oxidation Improved glycolysis and glucose oxidation Antioxidant activity Reduced endothelin-1 release Ranolazine Modulation of late sodium current, thereby reducing the accumulation of intracellular Ca** Increased glucose oxidation Lowered plasma glucose and HbA1C levels CPT-1 inhibitors Reduction of FFA oxidation Increased glucose oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Up-regulation of insulin secretion Improvement in insulin resistance		Induced insulin resistance (thiazide diuretics)
Activation of neuro-hormonal systems (loop diuretics) Increased glucosuria triggers lipolysis and fatty acid oxidation and ketone body synthesis in the liver Increased diuresis resulting in reduction in plasma volume and blood pressure Glucagon-like peptide 1 agonists Acetylsalicylic acid Reduction of circulating FFA, by activating AMP-activated protein kinase Activation of catabolic pathways (glucose uptake and FFA oxidation) Inhibition of the transcription factor NF-kappa B (improved glucose tolerance) Statins Pravastatin decreases the risk of development of diabetes Other statins including simvastatin, atorvastatin, and rosuvastatin increase the risk of development of diabetes All statins reduce serum testosterone levels Trimetazidine Reduction in fatty acid oxidation Improved glycolysis and glucose oxidation Antioxidant activity Reduced endothelin-1 release Modulation of late sodium current, thereby reducing the accumulation of intracellular Ca** Increased glucose oxidation Lowered plasma glucose and HbA1C levels Preduction of FFA oxidation Increased glucose oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Stimulation of insulin secretion Improvement in insulin resistance Induced weight gain and insulin resistance		Elevated parathyroid hormone level (loop diuretics)
Sodium-glucose cotransporter-2 inhibitors Increased glucosuria triggers lipolysis and fatty acid oxidation and ketone body synthesis in the liver Increased diuresis resulting in reduction in plasma volume and blood pressure Augmentation of insulin and inhibition of glucagon secretion Improve insulin resistance Promote weight loss Acetylsalicylic acid Reduction of circulating FFA, by activating AMP-activated protein kinase Activation of catabolic pathways (glucose uptake and FFA oxidation) Inhibition of the transcription factor NF-kappa B (improved glucose tolerance) Statins Pravastatin decreases the risk of development of diabetes Other statins including simvastatin, atorvastatin, and rosuvastatin increase the risk of development of diabetes All statins reduce serum testosterone levels Trimetazidine Reduction in fatty acid oxidation Improved glycolysis and glucose oxidation Antioxidant activity Reduced endothelin-1 release Modulation of lates sodium current, thereby reducing the accumulation of intracellular Ca** Increased glucose oxidation Lowered plasma glucose and HbA1C levels CPT-I inhibitors Reduction of FFA oxidation Increased glucose oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Stimulation of insulin secretion Improvement in insulin resistance Induced weight gain and insulin resistance		Induced electrolyte depletion (thiazide and loop diuretics)
and ketone body synthesis in the liver Increased diuresis resulting in reduction in plasma volume and blood pressure Augmentation of insulin and inhibition of glucagon secretion improve insulin resistance Promote weight loss Reduction of circulating FFA, by activating AMP-activated protein kinase Activation of catabolic pathways (glucose uptake and FFA oxidation) Inhibition of the transcription factor NF-kappa B (improved glucose tolerance) Statins Pravastatin decreases the risk of development of diabetes Other statins increase the risk of development of diabetes All statins reduce serum testosterone levels Reduction in fatty acid oxidation Improved glycolysis and glucose oxidation Antioxidant activity Reduced endothelin-1 release Modulation of late sodium current, thereby reducing the accumulation of intracellular Ca++ Increased glucose oxidation Lowered plasma glucose and HbA1C levels CPT-1 inhibitors Reduction of FFA oxidation Increased glucose oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Up-regulation of insulin secretion Improvement in insulin resistance Induced weight gain and insulin resistance		Activation of neuro-hormonal systems (loop diuretics)
and ketone body synthesis in the liver Increased diuresis resulting in reduction in plasma volume and blood pressure Augmentation of insulin and inhibition of glucagon secretion improve insulin resistance Promote weight loss Acetylsalicylic acid Reduction of circulating FFA, by activating AMP-activated protein kinase Activation of catabolic pathways (glucose uptake and FFA oxidation) Inhibition of the transcription factor NF-kappa B (improved glucose tolerance) Statins Pravastatin decreases the risk of development of diabetes Other statins including simvastatin, and rosuvastatin, and rosuvastatin increase the risk of development of diabetes All statins reduce serum testosterone levels Trimetazidine Reduction in fatty acid oxidation Improved glycolysis and glucose oxidation Antioxidant activity Reduced endothelin-1 release Modulation of late sodium current, thereby reducing the accumulation of intracellular Ca** Increased glucose oxidation Lowered plasma glucose and HbA1C levels CPT-1 inhibitors Reduction of FFA oxidation Increased glucose oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Up-regulation of insulin secretion Improvement in insulin resistance Psychotropic drugs Induced weight gain and insulin resistance		Increased glucosuria triggers lipolysis and fatty acid oxidation
Glucagon-like peptide 1 agonists - Augmentation of insulin and inhibition of glucagon secretion - Improve insulin resistance - Promote weight loss - Reduction of circulating FFA, by activating AMP-activated protein kinase - Activation of catabolic pathways (glucose uptake and FFA oxidation) - Inhibition of the transcription factor NF-kappa B (improved glucose tolerance) Statins - Pravastatin decreases the risk of development of diabetes - Other statins including simvastatin, atorvastatin, and rosuvastatin increase the risk of development of diabetes - All statins reduce serum testosterone levels Trimetazidine - Reduction in fatty acid oxidation - Improved glycolysis and glucose oxidation - Antioxidant activity - Reduced endothelin-1 release Ranolazine - Modulation of late sodium current, thereby reducing the accumulation of intracellular Ca++ - Increased glucose oxidation - Lowered plasma glucose and HbA1C levels CPT-I inhibitors - Reduction of FFA oxidation - Increased glucose oxidation - Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation - Up-regulation of insulin secretion - Improvement in insulin resistance - Induced weight gain and insulin resistance	2 minutors	and ketone body synthesis in the liver
Augmentation of insulin and inhibition of glucagon secretion		Increased diuresis resulting in reduction in plasma volume and
Acetylsalicylic acid Promote weight loss Reduction of circulating FFA, by activating AMP-activated protein kinase Activation of catabolic pathways (glucose uptake and FFA oxidation) Inhibition of the transcription factor NF-kappa B (improved glucose tolerance) Statins Pravastatin decreases the risk of development of diabetes Other statins including simvastatin, atorvastatin, and rosuvastatin increase the risk of development of diabetes All statins reduce serum testosterone levels Trimetazidine Reduction in fatty acid oxidation Improved glycolysis and glucose oxidation Antioxidant activity Reduced endothelin-1 release Modulation of late sodium current, thereby reducing the accumulation of intracellular Ca** Increased glucose oxidation Lowered plasma glucose and HbA1C levels CPT-I inhibitors Reduction of FFA oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Up-regulation of insulin secretion Improvement in insulin resistance Induced weight gain and insulin resistance		blood pressure
Improve insulin resistance Promote weight loss Reduction of circulating FFA, by activating AMP-activated protein kinase Activation of catabolic pathways (glucose uptake and FFA oxidation) Inhibition of the transcription factor NF-kappa B (improved glucose tolerance) Statins Pravastatin decreases the risk of development of diabetes Other statins including simvastatin, atorvastatin, and rosuvastatin increase the risk of development of diabetes All statins reduce serum testosterone levels Trimetazidine Reduction in fatty acid oxidation Improved glycolysis and glucose oxidation Antioxidant activity Reduced endothelin-1 release Modulation of late sodium current, thereby reducing the accumulation of intracellular Ca*+ Increased glucose oxidation Lowered plasma glucose and HbA1C levels CPT-I inhibitors Reduction of FFA oxidation Increased glucose oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Up-regulation of insulin secretion Improvement in insulin resistance Psychotropic drugs Induced weight gain and insulin resistance		Augmentation of insulin and inhibition of glucagon secretion
Reduction of circulating FFA, by activating AMP-activated protein kinase Activation of catabolic pathways (glucose uptake and FFA oxidation) Inhibition of the transcription factor NF-kappa B (improved glucose tolerance) Statins Pravastatin decreases the risk of development of diabetes Other statins including simvastatin, atorvastatin, and rosuvastatin increase the risk of development of diabetes All statins reduce serum testosterone levels Trimetazidine Reduction in fatty acid oxidation Improved glycolysis and glucose oxidation Antioxidant activity Reduced endothelin-1 release Ranolazine Modulation of late sodium current, thereby reducing the accumulation of intracellular Ca++ Increased glucose oxidation Lowered plasma glucose and HbA1C levels Province of FFA oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Improvement in insulin resistance Psychotropic drugs Induced weight gain and insulin resistance		Improve insulin resistance
kinase Activation of catabolic pathways (glucose uptake and FFA oxidation) Inhibition of the transcription factor NF-kappa B (improved glucose tolerance) Pravastatin decreases the risk of development of diabetes Other statins including simvastatin, atorvastatin, and rosuvastatin increase the risk of development of diabetes All statins reduce serum testosterone levels Trimetazidine Reduction in fatty acid oxidation Improved glycolysis and glucose oxidation Antioxidant activity Reduced endothelin-1 release Ranolazine Modulation of late sodium current, thereby reducing the accumulation of intracellular Ca++ Increased glucose oxidation Lowered plasma glucose and HbA1C levels CPT-1 inhibitors Reduction of FFA oxidation Increased glucose oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Improvement in insulin resistance Psychotropic drugs Induced weight gain and insulin resistance		Promote weight loss
Activation of catabolic pathways (glucose uptake and FFA oxidation) Inhibition of the transcription factor NF-kappa B (improved glucose tolerance) Statins Pravastatin decreases the risk of development of diabetes Other statins including simvastatin, atorvastatin, and rosuvastatin increase the risk of development of diabetes All statins reduce serum testosterone levels Trimetazidine Reduction in fatty acid oxidation Improved glycolysis and glucose oxidation Antioxidant activity Reduced endothelin-1 release Ranolazine Modulation of late sodium current, thereby reducing the accumulation of intracellular Ca++ Increased glucose oxidation Lowered plasma glucose and HbA1C levels CPT-I inhibitors Reduction of FFA oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Vitamin D Stimulation of insulin secretion Improvement in insulin resistance Psychotropic drugs Induced weight gain and insulin resistance	Acetylsalicylic acid	Reduction of circulating FFA, by activating AMP-activated protein
oxidation) Inhibition of the transcription factor NF-kappa B (improved glucose tolerance) Pravastatin decreases the risk of development of diabetes Other statins including simvastatin, atorvastatin, and rosuvastatin increase the risk of development of diabetes All statins reduce serum testosterone levels Pravastatin increase the risk of development of diabetes All statins reduce serum testosterone levels Reduction in fatty acid oxidation Improved glycolysis and glucose oxidation Antioxidant activity Reduced endothelin-1 release Ranolazine Modulation of late sodium current, thereby reducing the accumulation of intracellular Ca++ Increased glucose oxidation Lowered plasma glucose and HbA1C levels Reduction of FFA oxidation Increased glucose oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Vitamin D Stimulation of insulin secretion Improvement in insulin resistance Psychotropic drugs Induced weight gain and insulin resistance		
Inhibition of the transcription factor NF-kappa B (improved glucose tolerance) Pravastatin decreases the risk of development of diabetes Other statins including simvastatin, atorvastatin, and rosuvastatin increase the risk of development of diabetes All statins reduce serum testosterone levels Pravastatin increase the risk of development of diabetes All statins reduce serum testosterone levels Reduction in fatty acid oxidation Improved glycolysis and glucose oxidation Antioxidant activity Reduced endothelin-1 release Modulation of late sodium current, thereby reducing the accumulation of intracellular Ca++ Increased glucose oxidation Lowered plasma glucose and HbA1C levels CPT-I inhibitors Reduction of FFA oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Up-regulation of insulin secretion Improvement in insulin resistance Psychotropic drugs Induced weight gain and insulin resistance		
glucose tolerance) Pravastatin decreases the risk of development of diabetes Other statins including simvastatin, atorvastatin, and rosuvastatin increase the risk of development of diabetes All statins reduce serum testosterone levels Trimetazidine Reduction in fatty acid oxidation Improved glycolysis and glucose oxidation Antioxidant activity Reduced endothelin-1 release Modulation of late sodium current, thereby reducing the accumulation of intracellular Ca++ Increased glucose oxidation Lowered plasma glucose and HbA1C levels CPT-I inhibitors Reduction of FFA oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Up-regulation of insulin secretion Improvement in insulin resistance Psychotropic drugs Induced weight gain and insulin resistance		
Pravastatin decreases the risk of development of diabetes Other statins including simvastatin, atorvastatin, and rosuvastatin increase the risk of development of diabetes All statins reduce serum testosterone levels Trimetazidine Reduction in fatty acid oxidation Improved glycolysis and glucose oxidation Antioxidant activity Reduced endothelin-1 release Modulation of late sodium current, thereby reducing the accumulation of intracellular Ca++ Increased glucose oxidation Lowered plasma glucose and HbA1C levels CPT-1 inhibitors Reduction of FFA oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Improvement in insulin resistance Psychotropic drugs Induced weight gain and insulin resistance		
Other statins including simvastatin, atorvastatin, and rosuvastatin increase the risk of development of diabetes All statins reduce serum testosterone levels Trimetazidine Reduction in fatty acid oxidation Improved glycolysis and glucose oxidation Antioxidant activity Reduced endothelin-1 release Modulation of late sodium current, thereby reducing the accumulation of intracellular Ca++ Increased glucose oxidation Lowered plasma glucose and HbA1C levels CPT-I inhibitors Reduction of FFA oxidation Increased glucose oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Improvement in insulin resistance Psychotropic drugs Induced weight gain and insulin resistance	Statins	
rosuvastatin increase the risk of development of diabetes • All statins reduce serum testosterone levels • Reduction in fatty acid oxidation • Improved glycolysis and glucose oxidation • Antioxidant activity • Reduced endothelin-1 release Ranolazine • Modulation of late sodium current, thereby reducing the accumulation of intracellular Ca++ • Increased glucose oxidation • Lowered plasma glucose and HbA1C levels • Reduction of FFA oxidation • Increased glucose oxidation • Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation • Vitamin D • Stimulation of insulin secretion • Improvement in insulin resistance Psychotropic drugs • Induced weight gain and insulin resistance		
All statins reduce serum testosterone levels Reduction in fatty acid oxidation Improved glycolysis and glucose oxidation Antioxidant activity Reduced endothelin-1 release Ranolazine Modulation of late sodium current, thereby reducing the accumulation of intracellular Ca++ Increased glucose oxidation Lowered plasma glucose and HbA1C levels CPT-1 inhibitors Reduction of FFA oxidation Increased glucose oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Vitamin D Stimulation of insulin secretion Improvement in insulin resistance Psychotropic drugs Induced weight gain and insulin resistance		
Improved glycolysis and glucose oxidation Antioxidant activity Reduced endothelin-1 release Modulation of late sodium current, thereby reducing the accumulation of intracellular Ca++ Increased glucose oxidation Lowered plasma glucose and HbA1C levels CPT-I inhibitors Reduction of FFA oxidation Increased glucose oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Vitamin D Stimulation of insulin secretion Improvement in insulin resistance Psychotropic drugs Induced weight gain and insulin resistance		
Antioxidant activity Reduced endothelin-1 release Modulation of late sodium current, thereby reducing the accumulation of intracellular Ca++ Increased glucose oxidation Lowered plasma glucose and HbA1C levels CPT-I inhibitors Reduction of FFA oxidation Increased glucose oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Vitamin D Stimulation of insulin secretion Improvement in insulin resistance Psychotropic drugs Induced weight gain and insulin resistance	Trimetazidine	
Ranolazine Modulation of late sodium current, thereby reducing the accumulation of intracellular Ca++ Increased glucose oxidation Lowered plasma glucose and HbA1C levels CPT-I inhibitors Reduction of FFA oxidation Increased glucose oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Vitamin D Stimulation of insulin secretion Improvement in insulin resistance Psychotropic drugs Induced weight gain and insulin resistance		Improved glycolysis and glucose oxidation
Ranolazine Modulation of late sodium current, thereby reducing the accumulation of intracellular Ca++ Increased glucose oxidation Lowered plasma glucose and HbA1C levels Reduction of FFA oxidation Increased glucose oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Vitamin D Stimulation of insulin secretion Improvement in insulin resistance Psychotropic drugs Induced weight gain and insulin resistance		Antioxidant activity
accumulation of intracellular Ca++ Increased glucose oxidation Lowered plasma glucose and HbA1C levels CPT-I inhibitors Reduction of FFA oxidation Increased glucose oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Vitamin D Stimulation of insulin secretion Improvement in insulin resistance Psychotropic drugs Induced weight gain and insulin resistance		Reduced endothelin-1 release
Increased glucose oxidation Lowered plasma glucose and HbA1C levels CPT-I inhibitors Reduction of FFA oxidation Increased glucose oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Vitamin D Stimulation of insulin secretion Improvement in insulin resistance Psychotropic drugs Induced weight gain and insulin resistance	Ranolazine	Modulation of late sodium current, thereby reducing the
Lowered plasma glucose and HbA1C levels Reduction of FFA oxidation Increased glucose oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Vitamin D Stimulation of insulin secretion Improvement in insulin resistance Psychotropic drugs Induced weight gain and insulin resistance		accumulation of intracellular Ca++
Reduction of FFA oxidation Increased glucose oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Vitamin D Stimulation of insulin secretion Improvement in insulin resistance Psychotropic drugs Induced weight gain and insulin resistance		Increased glucose oxidation
Increased glucose oxidation Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Vitamin D Stimulation of insulin secretion Improvement in insulin resistance Psychotropic drugs Induced weight gain and insulin resistance		Lowered plasma glucose and HbA1C levels
Up-regulation of the expression of various enzymes involved in fatty acids beta-oxidation Stimulation of insulin secretion Improvement in insulin resistance Psychotropic drugs Induced weight gain and insulin resistance	CPT-I inhibitors	Reduction of FFA oxidation
fatty acids beta-oxidation Vitamin D Stimulation of insulin secretion Improvement in insulin resistance Psychotropic drugs Induced weight gain and insulin resistance		Increased glucose oxidation
Stimulation of insulin secretion Improvement in insulin resistance Psychotropic drugs Induced weight gain and insulin resistance		Up-regulation of the expression of various enzymes involved in
Improvement in insulin resistance Psychotropic drugs Induced weight gain and insulin resistance		fatty acids beta-oxidation
Psychotropic drugs • Induced weight gain and insulin resistance	Vitamin D	Stimulation of insulin secretion
		Improvement in insulin resistance
Decreased insulin secretion	Psychotropic drugs	Induced weight gain and insulin resistance
		Decreased insulin secretion

2/3

Atlas of Science another view on science https://atlasofscience.org

Tab. 1. Main metabolic effects of medications used for the treatment of patients with heart failure. Legend: ACE: angiotensin-converting enzyme; AMP: adenosine monophosphate; ATP: adenosine triphosphate; CPT-I: Carnitine palmitoyl transferase I; FFA: free fatty acids; HbA1c: glycated hemoglobin, NF-kappa B: nuclear factor-kappa B.

In conclusion, most routinely used cardiovascular drugs yield ancillary energy metabolic effects that can either be beneficial or detrimental. Metabolic effects may be peripheral and/or directly influencing cardiac metabolism. Physicians looking after cardiovascular patients should be aware of the ancillary effects of the main drugs used in the daily clinical practice. Some of these metabolic properties may represent a principal effect of single drugs. All these concepts should prompt us to monitor peripheral and cardiac metabolic levels and try to improve them. Evidence-based medicine takes into account the beneficial effects of drugs on hard end-points, obtained by clinical trials of relatively short duration and it cannot be excluded that over longer time periods these beneficial effects of drugs could be either eliminated or reinforced due to their ancillary energy metabolic effects. For these reasons, future trials of cardiovascular drugs should take into account the evaluation of specific action on metabolism in order to better define their prescription in cardiac patients with different metabolic risk profiles.

Alexandru V Florea ¹, Roberto Spoladore ², Gabriele Fragasso ^{1,2}

¹Università Vita-Salute San Raffaele, Milan, Italy

²Clinical Cardiology - Heart Failure Clinic, Ospedale San Raffaele, Milan, Italy

Publication

Metabolic effects of cardiovascular drugs.
Fragasso G, Margonato A, Spoladore R, Lopaschuk GD
Trends Cardiovasc Med. 2019 Apr

3/3